argenex SE $ARGX Shares Sold by PGGM Investments

PGGM Investments lowered its holdings in argenex SE (NASDAQ:ARGX) by 28.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 54,830 shares of the company’s stock after selling 21,869 shares during the quarter. PGGM Investments owned 0.09% of argenex worth $46,109,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Abound Wealth Management lifted its holdings in argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after acquiring an additional 32 shares during the period. Sound Income Strategies LLC acquired a new position in shares of argenex during the 4th quarter worth $28,000. Ameriflex Group Inc. acquired a new position in shares of argenex during the 3rd quarter worth $32,000. Aventura Private Wealth LLC acquired a new position in shares of argenex during the 4th quarter worth $38,000. Finally, Sunbelt Securities Inc. acquired a new position in shares of argenex during the 3rd quarter worth $36,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Performance

argenex stock opened at $806.46 on Tuesday. The stock has a market cap of $49.90 billion, a PE ratio of 35.91, a P/E/G ratio of 1.28 and a beta of 0.46. The stock has a 50-day moving average price of $769.12 and a 200 day moving average price of $815.62. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The firm had revenue of $1.31 billion during the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. On average, equities analysts predict that argenex SE will post 25.27 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ARGX shares. Wells Fargo & Company lifted their price target on argenex from $1,247.00 to $1,260.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Citizens Jmp lifted their price target on argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research note on Friday, February 27th. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Finally, Oppenheimer dropped their price objective on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research report on Thursday, April 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and a consensus price target of $1,017.78.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.